Back to Peptipedia
Growth HormoneApproved · US

Tesamorelin

Tesamorelin is a GHRH analogue. In the US, EGRIFTA WR is approved for excess abdominal fat in adults with HIV-associated lipodystrophy.

Approvals

US · ApprovedEU · Application withdrawn

Peptipedia explains research and prescribing information. It does not replace medical advice and is not an invitation to use a substance.

Research areas

Source-based short profile

Evidence matrix

Molecular identity
Confirmed

Tesamorelin is a defined GHRH analogue. The US approval applies to EGRIFTA WR, not to arbitrary compounded products.

Human research
Strong
Replication
Single research group
Clinical endpoints
Symptom- or function-related
Safety
Characterized by prescribing information or extensive studies
Approval
US · Approved

The dimensions are presented separately and are not combined into an overall score.

What the source shows

Approval covers a specific indication, not general weight loss.

Research gaps

  • ·Long-term cardiovascular safety is unresolved.
  • ·Short profile: not a complete benefit–risk assessment. Unlisted contraindications and interactions are not adequately established in this profile; missing information does not establish safety.